Sakar Healthcare Ltd vs Syncom Formulations India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Sakar Healthcare Ltd is ₹ 629.65 as of 05 May 15:30 . The P/E Ratio of Sakar Healthcare Ltd changed from 15.2 on March 2022 to 16.5 on March 2021 . This represents a CAGR of 1.65% over 5 yearsThe P/E Ratio of Syncom Formulations (India) Ltd changed from 46.2 on March 2022 to 0 on March 2021 . This represents a CAGR of -100.00% over 5 years The Market Cap of Sakar Healthcare Ltd changed from ₹ 231.35 crore on March 2022 to ₹ 176.64 crore on March 2021 . This represents a CAGR of -5.25% over 5 yearsThe Market Cap of Syncom Formulations (India) Ltd changed from ₹ 916.79 crore on March 2022 to ₹ 0 crore on March 2021 . This represents a CAGR of -100.00% over 5 years The revenue of Sakar Healthcare Ltd for the Dec '25 is ₹ 70.85 crore as compare to the Sep '25 revenue of ₹ 58.78 crore. This represent the growth of 20.53% The revenue of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 120.64 crore as compare to the Sep '25 revenue of ₹ 126.97 crore. This represent the decline of -4.99% The ebitda of Sakar Healthcare Ltd for the Dec '25 is ₹ 19.1 crore as compare to the Sep '25 ebitda of ₹ 12.57 crore. This represent the growth of 51.95% The ebitda of Syncom Formulations (India) Ltd for the Dec '25 is ₹ 26.71 crore as compare to the Sep '25 ebitda of ₹ 23.65 crore. This represent the growth of 12.94% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 10.25 crore over 7 quarters. This represents a CAGR of 128.70% The net profit of Syncom Formulations (India) Ltd changed from ₹ 7.63 crore to ₹ 18.91 crore over 7 quarters. This represents a CAGR of 67.97% The Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

About Syncom Formulations (India) Ltd

Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

FAQs for the comparison of Sakar Healthcare Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Sakar Healthcare Ltd or Syncom Formulations (India) Ltd?

Market cap of Sakar Healthcare Ltd is 1,400 Cr while Market cap of Syncom Formulations (India) Ltd is 1,321 Cr

What are the key factors driving the stock performance of Sakar Healthcare Ltd and Syncom Formulations (India) Ltd?

The stock performance of Sakar Healthcare Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Sakar Healthcare Ltd and Syncom Formulations (India) Ltd?

As of May 5, 2026, the Sakar Healthcare Ltd stock price is INR ₹629.65. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹14.06.

How do dividend payouts of Sakar Healthcare Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Sakar Healthcare Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.